Co-Diagnostics, Inc. Common Stock (NASDAQ:CODX) — Stock Price
Co-Diagnostics, Inc. Common Stock (NASDAQ:CODX) is currently trading at $1.50 USD, down 1.32% today. Over the past 52 weeks, shares have ranged between $0.17 and $11.19. This page tracks Co-Diagnostics, Inc. Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of Co-Diagnostics, Inc. Common Stock.
Co-Diagnostics, Inc. Common Stock (CODX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Co-Diagnostics, Inc. Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Co-Diagnostics, Inc. Common Stock Income Statement — Revenue, Profit & Earnings by Year
Co-Diagnostics, Inc. Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $622.49K | $3.92 Million | $6.81 Million | $34.22 Million | $97.89 Million |
| Cost of Revenue | $222.38K | $999.12K | $4.18 Million | $5.48 Million | $11.57 Million |
| Gross Profit | $400.11K | $2.92 Million | $2.63 Million | $28.74 Million | $86.31 Million |
| Research & Development | $19.14 Million | $20.98 Million | $22.96 Million | $17.44 Million | $14.96 Million |
| SG&A | $9.06 Million | $16.16 Million | $14.28 Million | $14.26 Million | $11.55 Million |
| Total Operating Expenses | $31.68 Million | $43.00 Million | $45.33 Million | $55.72 Million | $40.25 Million |
| Operating Income | $-31.28 Million | $-40.08 Million | $-42.71 Million | $-26.98 Million | $46.06 Million |
| EBITDA | $-30.18 Million | $-38.70 Million | $-41.48 Million | $-10.31 Million | $46.40 Million |
| EBIT | $-31.28 Million | $-40.08 Million | $-42.71 Million | $-11.59 Million | $46.06 Million |
| Interest Expense | — | — | — | $14.88 Million | $473.51K |
| Income Before Tax | $-48.51 Million | $-37.58 Million | $-38.11 Million | $-18.85 Million | $45.64 Million |
| Income Tax Expense | $-1.62 Million | $57.37K | $-2.78 Million | $-4.61 Million | $8.98 Million |
| Net Income | $-46.90 Million | $-37.64 Million | $-35.33 Million | $-14.24 Million | $36.66 Million |
Co-Diagnostics, Inc. Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Co-Diagnostics, Inc. Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $24.74 Million | $64.00 Million | $95.32 Million | $123.09 Million | $160.03 Million |
| Total Current Assets | $13.69 Million | $32.29 Million | $62.14 Million | $92.73 Million | $115.12 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $0.00 | $26.81 Million | $43.63 Million | $58.29 Million | $1.26 Million |
| Net Receivables | $190.38K | $132.57K | $330.88K | $5.40 Million | $20.91 Million |
| Inventory | $992.40K | $1.07 Million | $1.66 Million | $5.31 Million | $2.00 Million |
| Property, Plant & Equipment | — | — | — | $2.54 Million | $1.93 Million |
| Goodwill | — | — | — | $0.00 | $14.71 Million |
| Total Liabilities | $4.11 Million | $9.69 Million | $9.31 Million | $8.57 Million | $25.56 Million |
| Total Current Liabilities | $3.54 Million | $7.32 Million | $5.75 Million | $3.87 Million | $12.60 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-10.65 Million | $-784.37K | $-11.93 Million | $-22.63 Million | $-88.61 Million |
| Total Stockholder Equity | $20.63 Million | $54.31 Million | $86.01 Million | $114.52 Million | $134.48 Million |
| Retained Earnings | $-80.37 Million | $-33.04 Million | $4.60 Million | $39.93 Million | $54.17 Million |
Co-Diagnostics, Inc. Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Co-Diagnostics, Inc. Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-29.14 Million | $-29.16 Million | $-22.08 Million | $6.57 Million | $41.08 Million |
| Capital Expenditures | $700.05K | $748.35K | $1.37 Million | $1.43 Million | $669.46K |
| Free Cash Flow | $-29.84 Million | $-29.90 Million | $-23.45 Million | $5.14 Million | $40.41 Million |
| Investing Cash Flow | $26.27 Million | $17.07 Million | $15.39 Million | $-58.17 Million | $4.10 Million |
| Financing Cash Flow | $11.81 Million | $103.91K | $-1.36 Million | $-14.03 Million | $450.40K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $2.25 Million | $5.43 Million | $8.34 Million | $7.54 Million | $5.51 Million |
| Depreciation | $1.11 Million | $1.38 Million | $1.23 Million | $1.28 Million | $335.36K |
| Change in Cash | $8.95 Million | $-11.98 Million | $-8.06 Million | $-65.63 Million | $45.63 Million |
Co-Diagnostics, Inc. Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track Co-Diagnostics, Inc. Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 01, 2026 | -4.09 | -3.75 | -9.05% |
| Mar 19, 2026 | -4.44 | -0.13 | -3314.46% |
| Nov 13, 2025 | -0.16 | -0.16 | +0.00% |
| Aug 14, 2025 | -0.23 | -0.66 | +65.15% |
| May 07, 2025 | -0.26 | -0.33 | +22.00% |
| Mar 12, 2025 | -0.38 | -0.34 | -11.12% |
| Nov 07, 2024 | -0.32 | -0.33 | +3.03% |
| Aug 08, 2024 | -0.14 | -0.34 | +58.82% |